Top

Clinical Reviews in Allergy & Immunology

Published in:

01-04-2018

Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review

Authors: Massimo Cugno, Roberta Gualtierotti, Pier Luigi Meroni, Angelo Valerio Marzano

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2018

Abstract

Rheumatoid arthritis and spondyloarthritis are inflammatory joint disorders with an autoimmune pathogenesis and systemic involvement. The skin is one of the most frequently affected extraarticular sites with a number of manifestations or distinct diseases, including common conditions, such as rheumatoid nodules and psoriasis, and rare diseases like neutrophilic dermatoses. The latter are clinically characterised by polymorphic lesions, including pustules, bullae, abscesses, papules, nodules, plaques and ulcers, and histologically by neutrophil-rich inflammatory infiltrates. Inflammatory joint disorders and neutrophilic dermatoses share a number of pathophysiological features related to their cytokine overexpression profile. Moreover, any organ system can be potentially involved in neutrophilic dermatoses, giving rise to the concept of neutrophilic disease. Among the extracutaneous manifestations of neutrophilic disease, joint involvement is regarded as the most common. It is not associated with erosions and disability and usually responds to treatment for skin involvement, consisting of systemic corticosteroids and, in refractory cases, immunosuppressants or biologics. Arthritis may also be the initial manifestation of rheumatoid arthritis or spondyloarthritis, which has a chronic or recurrent course and requires a continuous treatment with synthetic or biologic disease-modifying anti-rheumatic drugs. If not properly treated, they may be associated with disability and reduced quality of life. Skin lesions occurring during the course of rheumatoid arthritis and spondyloarthritis require a multidisciplinary approach envisaging the collaboration of dermatologists and rheumatologists in order to achieve early diagnosis and treatment. Several biomarkers may help the clinician in the differential diagnosis of arthritis while histology is pivotal for the correct classification of the skin disease. However, in some cases, only regular follow-up allows a definite diagnosis. In this review article, we focus on the prototypic neutrophilic dermatoses like pyoderma gangrenosum, Sweet’s syndrome, hidradenitis suppurativa and their syndromic forms as well as on their articular involvement, providing a simple approach for their diagnosis and therapy.

Langan SM, Groves RW, Card TR, Gulliford MC (2012) Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 132(9):2166–2170. doi:10.1038/jid.2012.130 PubMedCrossRef

Levin J, Werth VP (2006) Skin disorders with arthritis. Best Pract Res Clin Rheumatol 20(4):809–826. doi:10.1016/j.berh.2006.05.001 PubMedCrossRef

Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, Wendling D, Aubin F, Liote F, Bachelez H (2014) Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol 41(3):490–494. doi:10.3899/jrheum.130977 PubMedCrossRef

Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2):183–196. doi:10.1016/j.immuni.2017.02.006 PubMedPubMedCentralCrossRef

Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, Meroni PL, Cugno M (2014) Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol 178(1):48–56. doi:10.1111/cei.12394 PubMedPubMedCentralCrossRef

Prat L, Bouaziz JD, Wallach D, Vignon-Pennamen MD, Bagot M (2014) Neutrophilic dermatoses as systemic diseases. Clin Dermatol 32(3):376–388. doi:10.1016/j.clindermatol.2013.11.004 PubMedCrossRef

Wallach D, Vignon-Pennamen MD (2006) From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol 55(6):1066–1071. doi:10.1016/j.jaad.2006.07.016 PubMedCrossRef

Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8 PubMedCrossRef

Malmstrom V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 17(1):60–75. doi:10.1038/nri.2016.124 PubMedCrossRef

10.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef

11.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. doi:10.1002/art.27584 PubMedCrossRef

12.

Sayah A, English JC 3rd (2005) Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 53(2):191–209; quiz 210-192. doi:10.1016/j.jaad.2004.07.023 PubMedCrossRef

13.

Stehlik C (2009) Multiple interleukin-1beta-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum 60(12):3524–3530. doi:10.1002/art.24961 PubMedPubMedCentralCrossRef

14.

Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. doi:10.1146/annurev.immunol.021908.132612 PubMedCrossRef

15.

Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L (2017) Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol 13(2):79–86. doi:10.1038/nrrheum.2016.200 PubMedCrossRef

16.

Ahmadi S, Powell FC (2005) Pyoderma gangrenosum: uncommon presentations. Clin Dermatol 23(6):612–620. doi:10.1016/j.clindermatol.2005.01.014 PubMedCrossRef

17.

von den Driesch P (1997) Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 137(6):1000–1005PubMedCrossRef

18.

Powell FC, Schroeter AL, Su WP, Perry HO (1985) Pyoderma gangrenosum: a review of 86 patients. Q J Med 55(217):173–186PubMed

19.

Gay-Crosier F, Dayer JM, Chavaz P, Hauser C (2000) Rheumatoid neutrophilic dermatitis/Sweet’s syndrome in a patient with seronegative rheumatoid arthritis. Dermatology 201(2):185–187PubMedCrossRef

20.

Yamauchi PS, Turner L, Lowe NJ, Gindi V, Jackson JM (2006) Treatment of recurrent Sweet’s syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 54(3 Suppl 2):S122–S126. doi:10.1016/j.jaad.2005.11.1089 PubMedCrossRef

21.

Cohen PR, Kurzrock R (2000) Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 18(3):265–282PubMedCrossRef

22.

Wolf R, Tuzun Y (2017) Acral manifestations of Sweet syndrome (neutrophilic dermatosis of the hands). Clin Dermatol 35(1):81–84. doi:10.1016/j.clindermatol.2016.09.011 PubMedCrossRef

23.

Ackerman AB (1978) Histologic diagnosis of inflammatory skin diseases: a method by pattern analysis. Lea & Febiger,

24.

Brown TS, Fearneyhough PK, Burruss JB, Callen JP (2001) Rheumatoid neutrophilic dermatitis in a woman with seronegative rheumatoid arthritis. J Am Acad Dermatol 45(4):596–600. doi:10.1067/mjd.2001.119031 PubMedCrossRef

25.

Mashek HA, Pham CT, Helm TN, Klaus M (1997) Rheumatoid neutrophilic dermatitis. Arch Dermatol 133(6):757–760PubMedCrossRef

26.

Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377(9783):2127–2137. doi:10.1016/S0140-6736(11)60071-8 PubMedCrossRef

27.

Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218–1227PubMedCrossRef

28.

Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57(2):85–89PubMed

29.

Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou CT, Doan T, Dowling A, Fialho RN, Gergely P, Gladman DD, Inman R, Kauppi M, Kaarela K, Laiho K, Maksymowych W, Pointon JJ, Rahman P, Reveille JD, Sorrentino R, Tuomilehto J, Vargas-Alarcon G, Wordsworth BP, Xu H, Brown MA, International Genetics of Ankylosing S (2008) Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 67(9):1305–1309. doi:10.1136/ard.2007.081364 PubMedCrossRef

30.

Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9):1041–1045. doi:10.1136/ard.2004.020800 PubMedPubMedCentralCrossRef

31.

Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298. doi:10.1136/ard.2004.023176 PubMedCrossRef

32.

Bennett AN, Tan AL, Coates LC, Emery P, Marzo-Ortega H, McGonagle D (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 47(2):223–224. doi:10.1093/rheumatology/kem302 CrossRef

33.

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73(2):349–356. doi:10.1136/annrheumdis-2012-202646 PubMedCrossRef

34.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633–640. doi:10.1016/S0140-6736(09)60140-9 PubMedCrossRef

35.

Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, Weedon H, Street S, Thomas R, Thomas GP, Brown MA (2012) Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum 64(5):1420–1429. doi:10.1002/art.33507 PubMedCrossRef

36.

Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58(8):2307–2317. doi:10.1002/art.23655 PubMedCrossRef

37.

Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128(5):1207–1211. doi:10.1038/sj.jid.5701213 PubMedCrossRef

38.

Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359(1–2):419–429. doi:10.1007/s11010-011-1036-6 PubMedCrossRef

39.

El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22(6):554–560. doi:10.1016/j.ejim.2011.06.006 PubMedCrossRef

40.

Jemec GB (2012) Clinical practice. Hidradenitis suppurativa. N Engl J Med 366(2):158–164. doi:10.1056/NEJMcp1014163 PubMedCrossRef

41.

Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C (2013) Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 149(6):762–764. doi:10.1001/jamadermatol.2013.2907 PubMedCrossRef

42.

van der Zee HH, van der Woude CJ, Florencia EF, Prens EP (2010) Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 162(1):195–197. doi:10.1111/j.1365-2133.2009.09430.x PubMedCrossRef

43.

van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP (2011) Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 164(6):1292–1298. doi:10.1111/j.1365-2133.2011.10254.x PubMedCrossRef

44.

Monnet D, Kadi A, Izac B, Lebrun N, Letourneur F, Zinovieva E, Said-Nahal R, Chiocchia G, Breban M (2012) Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis 71(6):885–890. doi:10.1136/annrheumdis-2011-200439 PubMedCrossRef

45.

Lima AL, Karl I, Giner T, Poppe H, Schmidt M, Presser D, Goebeler M, Bauer B (2016) Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol 174(3):514–521. doi:10.1111/bjd.14214 PubMedCrossRef

46.

Ambarus C, Yeremenko N, Tak PP, Baeten D (2012) Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol 24(4):351–358. doi:10.1097/BOR.0b013e3283534df4 PubMedCrossRef

47.

Delaney TA, Clay CD, Randell PL (1989) The bowel-associated dermatosis—arthritis syndrome. Australas J Dermatol 30(1):23–27PubMedCrossRef

48.

Brouard MC, Chavaz P, Borradori L (2004) Acute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowel-associated dermatosis-arthritis syndrome and pustular pyoderma gangrenosum. J Eur Acad Dermatol Venereol 18(1):89–92PubMedCrossRef

49.

Callen JP (2002) Neutrophilic dermatoses. Dermatol Clin 20(3):409–419PubMedCrossRef

50.

Shagrin JW, Frame B, Duncan H (1971) Polyarthritis in obese patients with intestinal bypass. Ann Intern Med 75(3):377–380PubMedCrossRef

51.

Kennedy C (1981) The spectrum of inflammatory skin disease following jejuno-ileal bypass for morbid obesity. Br J Dermatol 105(4):425–435PubMedCrossRef

52.

Slater GH, Kerlin P, Georghiou PR, Fielding GA (2004) Bowel-associated dermatosis-arthritis syndrome after biliopancreatic diversion. Obes Surg 14(1):133–135. doi:10.1381/096089204772787446 PubMedCrossRef

53.

Dicken CH (1986) Bowel-associated dermatosis-arthritis syndrome: bowel bypass syndrome without bowel bypass. J Am Acad Dermatol 14(5 Pt 1):792–796PubMedCrossRef

54.

Prpic-Massari L, Kastelan M, Brajac I, Cabrijan L, Zamolo G, Massari D (2007) Bowel-associated dermatosis-arthritis syndrome in a patient with appendicitis. Med Sci Monit 13(8):CS97–C100PubMed

55.

Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45(2):202–210. doi:10.1007/s12016-012-8351-x PubMedCrossRef

56.

Holt PJ, Davies MG, Saunders KC, Nuki G (1980) Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) 59(2):114–133CrossRef

57.

Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS (2009) Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 60(5):1242–1249. doi:10.1002/art.24433 PubMedCrossRef

58.

Nolla JM, Juanola X, Valverde J, Roig-Escofet D, Pagerols X, Servitge O (1990) Arthritis in acute febrile neutrophilic dermatosis (Sweet’s syndrome). Ann Rheum Dis 49(2):135PubMedPubMedCentralCrossRef

59.

McQueen FM (2013) Imaging in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 27(4):499–522. doi:10.1016/j.berh.2013.09.005 PubMedCrossRef

60.

Olivieri I, Costa AM, Cantini F, Niccoli L, Marini R, Ferri S (1996) Pyoderma gangrenosum in association with undifferentiated seronegative spondylarthropathy. Arthritis Rheum 39(6):1062–1065PubMedCrossRef

61.

Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35(6):727–734. doi:10.1155/2013/726598 PubMedPubMedCentralCrossRef

62.

Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases. Rev Rhum Mal Osteoartic 54(3):187–196PubMed

63.

Van Doornum S, Barraclough D, McColl G, Wicks I (2000) SAPHO: rare or just not recognized? Semin Arthritis Rheum 30(1):70–77. doi:10.1053/sarh.2000.8371 PubMedCrossRef

64.

Marzano AV, Borghi A, Meroni PL, Cugno M (2016) Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol 175(5):882–891. doi:10.1111/bjd.14691 PubMedCrossRef

65.

Liao HJ, Chyuan IT, Wu CS, Lin SW, Chen KH, Tsai HF, Hsu PN (2015) Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice. Rheumatology (Oxford) 54(7):1317–1326. doi:10.1093/rheumatology/keu481 CrossRef

66.

Rukavina I (2015) SAPHO syndrome: a review. J Child Orthop 9(1):19–27. doi:10.1007/s11832-014-0627-7 PubMedPubMedCentralCrossRef

67.

Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy R, Meyer O, Hayem G (2008) Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 47(8):1160–1167. doi:10.1093/rheumatology/ken185 CrossRef

68.

Qin M, Pirouz A, Kim MH, Krutzik SR, Garban HJ, Kim J (2014) Propionibacterium acnes induces IL-1beta secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol 134(2):381–388. doi:10.1038/jid.2013.309 PubMedCrossRef

69.

Sahdo B, Sarndahl E, Elgh F, Soderquist B (2013) Propionibacterium acnes activates caspase-1 in human neutrophils. APMIS 121(7):652–663. doi:10.1111/apm.12035 PubMedCrossRef

70.

Firinu D, Barca MP, Lorrai MM, Perra S, Cabras S, Muggianu E, Di Martino ML, Manconi PE, Del Giacco SR (2014) TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity 47(6):389–394. doi:10.3109/08916934.2014.906582 PubMedCrossRef

71.

Kahn MF, Khan MA (1994) The SAPHO syndrome. Baillieres Clin Rheumatol 8(2):333–362PubMedCrossRef

72.

Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME (2012) The SAPHO syndrome. Semin Arthritis Rheum 42(3):254–265. doi:10.1016/j.semarthrit.2012.05.006 PubMedCrossRef

73.

Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffman O, Kahn MF, Meyer O (1999) SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 29(3):159–171PubMedCrossRef

74.

Freyschmidt J, Sternberg A (1998) The bullhead sign: scintigraphic pattern of sternocostoclavicular hyperostosis and pustulotic arthroosteitis. Eur Radiol 8(5):807–812. doi:10.1007/s003300050476 PubMedCrossRef

75.

Naves JE, Cabre E, Manosa M, Grados D, Olive A, Domenech E (2013) A systematic review of SAPHO syndrome and inflammatory bowel disease association. Dig Dis Sci 58(8):2138–2147. doi:10.1007/s10620-013-2653-6 PubMedCrossRef

76.

Kundu BK, Naik AK, Bhargava S, Srivastava D (2013) Diagnosing the SAPHO syndrome: a report of three cases and review of literature. Clin Rheumatol 32(8):1237–1243. doi:10.1007/s10067-013-2251-1 PubMedCrossRef

77.

Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72(7):611–615. doi:10.1016/S0025-6196(11)63565-9 PubMedCrossRef

78.

Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11(8):961–969PubMedCrossRef

79.

Yeon HB, Lindor NM, Seidman JG, Seidman CE (2000) Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 66(4):1443–1448. doi:10.1086/302866 PubMedPubMedCentralCrossRef

80.

Hsieh J, Kadavath S, Efthimiou P (2014) Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol 33(5):601–608. doi:10.1007/s10067-013-2436-7 PubMedCrossRef

81.

Cugno M, Borghi A, Marzano AV (2017) PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol 18(4):555–562. doi:10.1007/s40257-017-0265-1

82.

Donmez S, Pamuk ON, Gedik M, KR A, Bulut G (2014) A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab. Int J Rheum Dis 17(4):471–475. doi:10.1111/1756-185X.12274 PubMedCrossRef

83.

Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M (2014) Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 47(3):146–153. doi:10.3109/08916934.2013.873414 PubMedCrossRef

84.

Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R (2007) Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 26(12):2205–2206. doi:10.1007/s10067-007-0733-8 PubMedCrossRef

85.

Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G (2008) Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol 144(6):817–818. doi:10.1001/archderm.144.6.817 PubMedCrossRef

86.

Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, Yamamoto T (2012) Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol 22(6):804–805. doi:10.1684/ejd.2012.1849 PubMedCrossRef

87.

Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L (2013) Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges 11(5):447–449. doi:10.1111/ddg.12032 PubMedCrossRef

88.

Wendling D, Prati C (2014) Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases. Expert Rev Clin Immunol 10(1):159–169. doi:10.1586/1744666X.2014.866038 PubMedCrossRef

89.

Akahoshi-Ikeda M, Yoshizawa S, Motoshita J, Furue M, Takeuchi S (2016) A case of pyoderma gangrenosum in a patient with rheumatoid arthritis treated with abatacept. Acta Derm Venereol 96(6):822–823. doi:10.2340/00015555-2380 PubMedCrossRef

90.

Tiwari SM, Wood BA, Skender-Kalnenas T, Cook N (2014) A case of abatacept associated neutrophilic dermatosis and a review of the literature. Australas J Dermatol 55(3):214–217. doi:10.1111/ajd.12185 PubMedCrossRef

91.

Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, Juarez-Reyes A, Monsivais-Urenda A, Baranda L, Gonzalez-Amaro R (2011) CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 31(4):588–595. doi:10.1007/s10875-011-9527-5 PubMedCrossRef

92.

Anderson DE, Bieganowska KD, Bar-Or A, Oliveira EM, Carreno B, Collins M, Hafler DA (2000) Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat Med 6(2):211–214. doi:10.1038/72323 PubMedCrossRef

93.

Reichrath J, Bens G, Bonowitz A, Tilgen W (2005) Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53(2):273–283. doi:10.1016/j.jaad.2004.10.006 PubMedCrossRef

94.

Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR (2010) Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 62(4):646–654. doi:10.1016/j.jaad.2009.05.030 PubMedCrossRef

95.

Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509. doi:10.1136/gut.2005.074815 PubMedPubMedCentralCrossRef

96.

Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC, Team UKDCTNsSG (2015) Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350:h2958. doi:10.1136/bmj.h2958 PubMedPubMedCentralCrossRef

97.

Maalouf D, Battistella M, Bouaziz JD (2015) Neutrophilic dermatosis: disease mechanism and treatment. Curr Opin Hematol 22(1):23–29. doi:10.1097/MOH.0000000000000100 PubMedCrossRef

98.

Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC, Team UKDCTNsSG (2016) Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. J Am Acad Dermatol 75(5):940–949. doi:10.1016/j.jaad.2016.06.016 PubMedCrossRef

99.

Chokoeva AA, Cardoso JC, Wollina U, Tchernev G (2017) Pyoderma gangrenosum—a novel approach? Wien Med Wochenschr 167(3–4):58–65. doi:10.1007/s10354-016-0472-z PubMedCrossRef

100.

Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161(5):1199–1201. doi:10.1111/j.1365-2133.2009.09404.x PubMedCrossRef

101.

Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R (2013) Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 149(2):209–215. doi:10.1001/2013.jamadermatol.717 PubMedCrossRef

102.

Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Rocken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE (2015) Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 173(5):1216–1223. doi:10.1111/bjd.14037 PubMedCrossRef

103.

Krause K, Tsianakas A, Wagner N, Fischer J, Weller K, Metz M, Church MK, Maurer M (2017) Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol 139(4):1311–1320. doi:10.1016/j.jaci.2016.07.041 PubMedCrossRef

104.

Stichweh DS, Punaro M, Pascual V (2005) Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 22(3):262–265. doi:10.1111/j.1525-1470.2005.22320.x PubMedCrossRef

105.

Tofteland ND, Shaver TS (2010) Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol 16(5):244–245. doi:10.1097/RHU.0b013e3181e969b9 PubMedCrossRef

106.

Lee H, Park SH, Kim SK, Choe JY, Park JS (2012) Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin Exp Rheumatol 30(3):452PubMed

107.

Marzano AV, Ceccherini I, Gattorno M, Fanoni D, Caroli F, Rusmini M, Grossi A, De Simone C, Borghi OM, Meroni PL, Crosti C, Cugno M (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore) 93(27):e187. doi:10.1097/MD.0000000000000187 CrossRef

108.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, Group ES, Group FS (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371(4):326–338. doi:10.1056/NEJMoa1314258 PubMedCrossRef

109.

Burkett PR, Kuchroo VK (2016) IL-17 blockade in psoriasis. Cell 167(7):1669. doi:10.1016/j.cell.2016.11.044 PubMedCrossRef

110.

Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA (2016) CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature—a rare case with a novel mutation. Eur J Pediatr 175(5):735–740. doi:10.1007/s00431-015-2668-4 PubMedCrossRef

111.

Mitragotri S, Yoo JW (2011) Designing micro- and nano-particles for treating rheumatoid arthritis. Arch Pharm Res 34(11):1887–1897. doi:10.1007/s12272-011-1109-9 PubMedCrossRef

112.

Simonetta F, Allali D, Roux-Lombard P, Chizzolini C (2017) Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine 84(2):235–236. doi:10.1016/j.jbspin.2016.01.008 PubMedCrossRef

113.

Kraaij T, Huizinga TW, Rabelink TJ, Teng YK (2014) Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 53(11):2122–2124. doi:10.1093/rheumatology/keu369 CrossRef

Title: Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review
Authors: Massimo Cugno
Roberta Gualtierotti
Pier Luigi Meroni
Angelo Valerio Marzano
Publication date: 01-04-2018
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2018
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-017-8629-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Myeloid Cells and Chronic Liver Disease: a Comprehensive Review

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review

Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland

Chitin and Its Effects on Inflammatory and Immune Responses

Unmet Needs in the Pathogenesis and Treatment of Vasculitides

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials